Meetings of the Library (Scientific Research) Section have lately been devoted to some of the future influences, especially of the European Community (EC), on clinical practice and research. In May 1989, the effect of European harmonization on the safety monitoring of medicines was discussed and this was followed in January 1990 by a consideration of ethics in clinical development. The most recent meeting was devoted to the concept of 'Good Clinical Practice' and the guidelines that have evolved from the deliberations of the Committee on Proprietary Medicinal Products (CPMP). The title of the meeting was devised to encourage debate of the issues for and against the implementation of the new European guidelines; in the event the word 'pros' could have stood for professionals and 'cons' for conventionality.
The regulatory view This was given by Dr Paul Adams (Principal Medical Officer at the Medicines Control Agency) who said that the member states of the EC shared a common position on 'Good Clinical Practice' (GCP) but he also predicted that GCP would become a topic as hot as global warming during the next year or two. As the EC bureaucrats are apparently united in their views on GCP, it must be assumed that the predicted generation of heat will result from the impact of GCP on those who have to implement it.
The CPMP had approved GCP guidelines in May 1990 and they will be applied throughout Europe to clinical investigations of medicinal products which are intended for inclusion in product licence applications. Implementation of these GCP guidelines has the objective of ensuring the accuracy of results from clinical trials for which the member states of the EC will share responsibility in a harmonized Europe. GCP requires the use of systematic procedures to provide a retrospective view of a clinical investigation and audit of the data, to verify the results obtained. In other words, claimed Dr Adams, GCP means good science and good ethics, which together should make good business sense to the pharmaceutical industry.
The EC conducts its business in eight languages and so it is hardly surprising that the terminology used in the guidelines caused difficulties and debate, yet it was considered important to achieve a common glossary of terms. Dr Adams hoped that the CPMP guidelines would become a useful compendium for international understanding. He dealt with such topics as case report forms which, in this age of computers, are not necessarily represented by paper but can be in electronic form, the transposition of data, the question of confidentiality and its interrelationship with medical ethics and informed consent. A proper understanding of the terms quality assurance (QA) and quality control (QC), as they apply to the collection and management of data from clinical trials, is essential and this also brought into consideration standard operating procedures (SOPs) as the means by which GCP can be applied.
The CPMP guidelines were claimed to include the first unified European statement on the protection of subjects who are involved in clinical research. There is no consolidated legislation on this subject. The Declaration of Helsinki and subsequent amendments form the basis of the content on informed consent. Ethics committees do not exist in all EC countries and, where they do, they operate by different rules. The GCP guidelines can, therefore, only give broad recommendations on how to approach matters requiring independent ethical consideration.
The GCP guidelines contain an appendix covering the handling of data, the application of statistics and the archiving of clinical trial records.
Much of the content of the CPMP guidelines on GCP will already be familiar to those in the pharmaceutical industry who are involved with clinical research but the guidelines now provide a unified standard applicable throughout the EC which compares with the standards already applied in the USA and Japan. The introduction of these guidelines on GCP does not imply that past standards have been deficient, but these CPMP guidelines should give all EC countries confidence that similar standards on the conduct of clinical research and the protection of patients will be applied throughout the Community. At present, a unified European product licence is due to be introduced in 1996 and so there will be a gradual movement from harmonization by consensus to harmonization by regulation.
The industry view Dr Richard Rondel (Director of the Oxford Workshops), a consultant to the pharmaceutical industry since 1981, said that, unlike Dr Adams who was able to represent a regulatory body, he could not claim to give the authoritative viewpoint of the pharmaceutical industry although, in his role as a consultant, he knew the problems which the industry faced and he has been involved in attempting to resolve some of them. Dr Rondel was the Medical Director, in the UK, of an American pharmaceutical company in the 1970s when the Food and Drug Administration (FDA) guidelines on GCP had been introduced. At that time, there had been considerable scepticism in Europe about conducting clinical research to FDA standards but it now transpires that Europe has followed the American lead with its own supranational GCP guidelines. To some extent, the impetus for the CPMP guidelines on GCP came from the multinational pharmaceutical companies who saw the need for unified standards of practice in the conduct of their international clinical research.
Dr Rondel approached the subject by giving his personal views on certain issues which he selected as being significant aspects of GCP in Europe. There were six of these: ethical issues; clinical investigators; clinical trial monitoring; QA and QC; advantages and disadvantages; and costs.
In Europe, clinical research has to be conducted to the standards specified in the Declaration of Helsinki, as subsequently modified, or of the individual country concerned, whichever gives the greater protection to the subject. However, the Declaration of Helsinki is couched in rather general terms, particularly where the composition and operation of ethics committees are concerned. The composition of ethics committees should become more openly known and they should be required to conduct their affairs according to specified procedures. A few years ago it was considered that informed consent was not obtainable in many countries in Europe but it is now obtained routinely for clinical research, in most cases in writing. Thus, the rather general ethical standards of the Declaration of Helsinki are being supplanted by more formal and specific requirements and this trend is likely to continue.
Good manufacturing practice (GMP) and good laboratory practice (GLP) have been established in the pharmaceutical industry for many years so that GCP is not a strange notion and, indeed, is in an advanced stage of development in many companies. However, it is still a novel concept in the medical community at large. The individual responsibilities of clinical investigators within GCP guidelines will need to be explained, perhaps by the pharmaceutical industry. The application of GCP principles will require an increase in resources at the clinical research site and this expansion may have to be funded by the pharmaceutical industry, especially in the UK where the NHS already has financial problems.
Archiving of clinical trial records, including case report forms, requires a considerable investment in resources. There is no agreed requirement for the duration of keeping trial records but in Sweden it is 15 years and in Germany 10 years. To keep trial records for such long periods and to make them readily retrievable for audit, as some companies have already recognized, requires a substantial investment in organized fire-proof and water-proof storage facilities, not only for the companies, but also for their investigators.
The standards of industry's monitoring of clinical trials has improved considerably throughout Europe as a consequence of introducing GCP, with the recruitment of many scientists as Clinical Research Associates in Medical Departments of pharmaceutical companies. This expansion of personnel has important cost implications and there is already evidence of its impact in the movement towards contracting out clinical research to external organizations which specialize in this work.
One of the most important elements ofGCP for the pharmaceutical industry is quality assurance (QA) and quality control (QC). A working definition of QA might be the use of a series of pre-established measures to ensure that the required quality is obtained. QA was formerly a retrospective activity but this is changing to the application of appropriate checks during pre-study, in-study, and post-study phases to monitor quality continuously throughout a trial. This practice makes standard operating procedures (SOPs) essential before a trial starts since GCP requires investigations to comply with SOP guidelines on each of the critical activities of a clinical investigation. The requirement for auditing data raises the question of their ownership. Dr Rondel thought that, in France, data were considered to Journal of the Royal Society of Medicine Volume 83 October 1990 655 belong to the patient to whom they applied but that elsewhere in Europe they were thought to belong to the state: of course, clinical investigators believed that clinical trial data belonged to them. Whatever the true position may be, it is difficult to monitor and audit the source data. The issue of ownership will have to be resolved as regulatory inspections of clinical investigators and their sites will take place with increasing frequency.
The potential disadvantages of GCP include apprehension of introducing a legalistic disposition to clinical research with a consequent increase in costs and loss of investigator support. The system for GCP in Europe is voluntary and so it is without legal sanctions but pharmaceutical companies and their clinical investigators will be expected to follow the CPMP guidelines and any deviation is likely to require an explanation. The only sanction that presently exists is compliance with the general climate of opinion on clinical research but future penalties, financial and others, can be foreseen.
In contrast, the benefits to the pharmaceutical industry will include the performance of fewer studies of better quality to achieve the granting of a product licence and better mutual recognition of studies done throughout Europe to speed up the regulatory process.
Costs are inseparable from all of the preceding considerations and the issue can be distilled into a choice between decreasing the clinical trial load and keeping the Medical Department's staff at the same level, or maintaining the clinical trial throughput and augmenting the resources (manpower, money, infrastructure) to cope with the additional work created by GCP. While Dr Rondel mentioned figures between 15 and 30% per annum as the increase in costs involved, the opinion of one member of the audience was that the true figure would be nearer to 50%.
The European experience
The third and final speaker, Dr Lucien Steru (Managing Director of the French Clinical Research Organization ITEM), concentrated on French experience with GCP rather than its wider European application. He acknowledged that the UK has a strong tradition of clinical research which is respected and has been copied elsewhere. GLP and GMP were already widely applied to the basic laboratory sciences and to manufacturing technology and similar principles had been developed in the USA for GCP and had been applied in the European subsidiaries of American companies. France had pragmatically adapted these GCP principles and, Dr Steru claimed, was the first European country to issue GCP guidelines and to set up an inspectorate. Now GCP would be introduced into the UK from continental Europe.
In France, in the 1950s, 1960s and 1970s clinical investigations depended on asking chosen professors to give their opinion of a certain medicine after they had tried it on some of their patients, what Dr Steru termed 'arrogance in pharmacy's golden years'. By contrast, doctors now had to make an effort to establish themselves as approved clinical investigators.
In 1986, a committee was set up in France to consider GCP and in 1987 it issued its recommendations. As a consequence, in 1988 the 'Loi Huriet' on clinical research was voted unanimously in the French Senate and in December 1988 the first decree, on informed consent, was put into practice; the law was revised in January 1990. The 'Loi Huriet' had little impact on the general public but it increased the awareness of the medical profession to clinical research and the requirements of GCP. It is widely believed that GCP will increase the credibility of the results from clinical research in France. Enforcement ofGCP in France is by an inspectorate backed by the law -'Loi Huriet'.
There are a number of unresolved issues such as the lack of GCP certification showing that the principles of GCP have been applied to a given clinical study. Also, there is no legal right of access to the source documents in France, not even for adverse event data, if no benefit accrues to the individual patient, and it will be necessary to find a way of examining source data for audit while maintaining confidentiality for the patient. The practical operation of the Committees for the Protection of Persons Participating in Medical Research, which have taken the place of ethics committees, has still to be determined. There is also the question of acceptability of European clinical trials to the FDA. In 1989, FDA inspectors audited 51 non-American clinical research centres including 20 in Canada and 10 in the Netherlands, but only two in England and one each in Scotland, France and Germany.
Inspectors for monitoring GCP in France, both doctors and pharmacists, have been trained and can enforce the law in a similar way to tax auditors; the penalties include fines of up to 200000 Francs and up to 2 years in prison for carrying out clinical trials without the consent of the patient, or approval of an ethics committee, or not complying with GCP standards; penalties can be applied equally to the sponsor and the investigator. Unlike the USA, there is no 'black list' of transgressors to disqualify unsuitable investigators. The aim of an inspection is verification of conformity to GCP and the validity of the data from the trial and it is done in two stages, the first covering the systems (sponsor, site, etc.) and the second the data. The first inspection of any institution is carried out on a voluntary basis possibly to make participants familiar with the procedure and purpose of the audit.
One important point, which Dr Steru stressed is that GCP can never make up for basic inadequacies in clinical trial design.
Aspects of AIDS
Keywords: AIDS; Pneumocystis carinii pneumonia; cytomegalovirus; Karposi'e sarcoma; non-Hodgkin's lymphoma There was material of interest to both therapists and diagnosticians in the Section given at this meeting.
Dr Fiona Moss (St Mary's Hospital, London) took us through the quite complex respiratory aspects. In addition to Pneumocystis carinii pneumonia (PCP) (the most frequent respiratory complication of the acquired immunodeficiency syndrome (AIDS», Mycobacterium tuberculosis (MTB)and Mycobacterium avium intracellulare infection, bacterial pneumonias, The reactions of French clinical investigators to the introduction of GCP included complaints about adjusting to the new concept of informed consent, longer consultations with patients to deal with this and other aspects of trials, the loss of patients to other doctors who are not involved in clinical research and too much paper work and record keeping. GCP is also inimical to the aims of Phase IV clinical trials which are designed to determine the behaviour of a medicine in normal clinical practice.
However, the advantages of implementing GCP include generating a healthy and helpful climate between investigators, regulators and sponsors, improving the perception of clinical research and the reputation of clinical investigators, helping patients to comply with their treatments, and probably increasing the power of clinical trials.
Elsewhere in Europe, the Spanish have declared their intention of implementing GCP and monitoring its application by their Health Inspectorate, and certain general regulations applicable to clinical trials and GCP were issued in Germany earlier this year.
In conclusion, Dr Steru said that GCP is here to stay as it could be viewed as protection for the consumer and there could be no reversal of such safeguards. Furthermore, GCP is already established in the USA and Japan and Europe could not be seen to do any less. GCP could change the structure and development of clinical trials in Europe but it must not be allowed to substitute for good scientific method and practice.
This was a meeting that called to mind, perhaps unfairly, a 50-year-old aphorism: 'Too much emphasis on standards is a cause of decay; often it is a psychological defense mechanism set up by persons no longer productive.' (l Starr, J Clin Invest 1940; 19:765) . The warnings by the speakers against over-emphasizing the influence and worth of GCP will have to heeded if clinical research is to continue to benefit patients through the rapid identification and introduction of valuable new treatments. After all, GCP should be the servant of clinical research and not allowed to become some fearful monster.
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Editorial Representative Library (Scientific Research) Section fungous infections (uncommon), cytomegalus inclusion virus (CMV) (uncommon), interstitial pneumonitis and pulmonary Kaposi's sarcoma (KS) were all considered.
There is a wide spectrum of severity, overlap of symptoms, atypical presentations and, in about 15% of AIDS patients with respiratory symptoms, more than one respiratory pathology is present. Most diagnoses can be made by bronchoscopy and bronchoalveolar lavage (BAL).
PCP, first described in 1940, occurred in immunodeficient patients but had a particular association with AIDS. Onset is insidious, from one week to 3 months, with worsening respiratory symptoms including fever and weight loss. Classical radiographic appearances are progressive fine perihilar 
